Compare SEV & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEV | PYPD |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | Israel |
| Employees | 46 | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2M | 85.1M |
| IPO Year | N/A | 2014 |
| Metric | SEV | PYPD |
|---|---|---|
| Price | $2.17 | $4.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | ★ 219.1K | 138.0K |
| Earning Date | 05-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,757.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $3.06 |
| 52 Week High | $11.24 | $5.21 |
| Indicator | SEV | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 60.06 |
| Support Level | $1.97 | $4.18 |
| Resistance Level | $3.26 | $5.09 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 50.27 | 80.00 |
Aptera Motors Corp engages in the development, production, and distribution of energy efficient solar-powered, battery-electric vehicles. The company has designed the Aptera vehicle to provide up to an estimated 40 miles per day by collecting energy from the sun and storing it in its proprietary battery pack. The company operates as a single reportable segment focused on the development of solar electric vehicles.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.